Brodalumab: 8 agencies, 2017–2022
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Where brodalumab met resistance it was usually narrowed rather than refused: 3 of 8 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
Assessment has run over 5.3 years, from 28 Mar 2017 at AWMSG (Wales) to 11 Jul 2022 at HAS (France).
HAS (France) changed its position: not recommended on 4 Apr 2018, recommended by 11 Jul 2022, after a resubmission.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
AWMSG (Wales) was first to assess brodalumab, on 28 Mar 2017; SMC (Scotland) did not open a file until 7 May 2018 — a moderate spread of 1.2 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 5 of 9 dated records fall in 2018 alone.
Restriction is doing real work here: 3 of 8 decisive outcomes narrowed brodalumab to a subgroup rather than accepting or refusing it outright, at G-BA (Germany), SMC (Scotland) and TLV (Sweden).
HAS (France) is the only agency to have returned to brodalumab, recording 2 separate entries.
8 of the 18 agencies in this archive hold a record for brodalumab.
The full ledger for brodalumab reads 4 recommended, 3 restricted, 1 not recommended and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 11 Jul 2022 | Re-assessment of SMR and ASMR | SMR substantial · ASMR V | source |
| SMC (Scotland) | 7 May 2018 | For the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy. | accepted (restricted) | source |
| NICE (England) | 21 Mar 2018 | NICE TA511 | recommended | source |
| DMC (Denmark) | 15 Mar 2018 | Moderat til svær plaque-psoriasis | Anbefalet | source |
| G-BA (Germany) | 1 Mar 2018 | Kyntheum — benefit assessment §35a | added benefit: non-quantifiable (indication) | source |
4 further decisions for brodalumab, across 4 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 9 decisions for brodalumab from 8 agencies, 2017 to 2022. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.